[Federal Register Volume 79, Number 30 (Thursday, February 13, 2014)]
[Notices]
[Page 8724]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-03083]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Tumor Infiltrating Lymphocytes From Human Papillomavirus-Positive
Tumors for the Treatment of Cancer
Description of Technology: Human papillomaviruses (HPV) cause
anogenital and oropharyngeal cancers, and these malignancies express
viral oncoproteins that can be recognized by T cells. When HPV-
associated cancers spread they are incurable and difficult to palliate
with existing treatments.
Tumor infiltrating lymphocytes (TIL) have been used successfully to
treat advanced stage malignant melanoma, however their use has been
primarily limited to this disease. This technology describes a novel
TIL therapy for treating HPV-associated cancers. The NIH inventors have
found TIL can be grown from HPV positive tumors at grade and scale
suitable for clinical use and that they can recognize the HPV
oncoproteins that drive transformation and survival of cancer cells.
The inventors have initiated a clinical trial for the treatment of
advanced HPV positive cancers that are refractory to standard
chemotherapy using HPV-TIL. Early results of the clinical trial suggest
that HPV-TIL has activity in chemotherapy-refractory advanced disease
for which no standard treatment options are available.
Potential Commercial Applications: HPV-TIL therapy is a novel
treatment approach that may mediate long-lasting tumor regression from
a single dose of cells.
Competitive Advantages: Early clinical results suggest that HPV-TIL
has activity in chemotherapy-refractory advanced disease for which no
standard treatment options are available.
Development Stage: In vitro data available (human)
Inventors: Christian Hinrichs and Steven A. Rosenberg (NCI)
Publications:
1. Piersma SJ, et al. Human papilloma virus specific T cells
infiltrating cervical cancer and draining lymph nodes show remarkably
frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer
2008 Feb 1;122(3):486-94. [PMID 17955486]
2. de Vos van Steenwijk PJ, et al. An unexpectedly large polyclonal
repertoire of HPV-specific T cells is poised for action in patients
with cervical cancer. Cancer Res. 2010 Apr 1;70(7):2707-17. [PMID
20233872]
Intellectual Property: HHS Reference No. E-494-2013/0--US
Provisional Application No. 61/846,161 filed 15 July 2013
Related Technology: HHS Reference No. E-495-2013/0--US Provisional
Application No. 61/846,167 filed 15 July 2013
Licensing Contact: Whitney A. Hastings; 301-451-7337;
[email protected]
Improved Culture Medium for Stem Cell Maintenance and Differentiation
Description of Technology: A novel low protein culture medium with
defined chemical components that allows pluripotent stem cell
maintenance and differentiation is disclosed. The present technology
also provides for production of high quality cardiac cells from human
embryonic and induced pluripotent stem cells in chemically defined
medium conditions. Human pluripotent stem cells, including human
embryonic stem cells and human induced pluripotent stem cells, can be
propagated indefinitely while still retaining the capacity to
differentiate into all somatic cell types, and are a potentially
inexhaustible supply of human cells. The capacity to sustain survival
at high density is critical for maintaining consistent stem cell
cultures and avoiding the development of abnormal stem cells, and for
proper stem cell differentiation. Also, it is essential to have high
quality stem cells for all personalized cellular therapies. NIH
investigators developed a low protein medium that supports the
proliferation and differentiation of stem cells comprising one or more
of a volume expander, a lipid mix and a growth factor modulator. Also,
the investigators have used the new medium to produce high quality
cardiac cells from human embryonic and induced pluripotent stem cells.
Potential Commercial Applications:
Improved defined medium to grow, maintain and
differentiate stem cells.
This medium can be used to develop culture systems that
could be used to generate specific cell types for potential clinical
applications.
Competitive Advantages: This new medium could significantly improve
progenitor cell derivation from embryonic stem cells and induced
pluripotent stem cells and could have great usage in future
translational applications.
Development Stage:
Early-stage
In vitro data available
In vivo data available (animal)
Inventors: Guokai Chen and Yongshun Lin (NHLBI)
Intellectual Property: HHS Reference No. E-089-2013/0--US
Provisional Application No. 61/879,840 filed 19 September 2013
Licensing Contact: Sury Vepa, Ph.D., J.D.; 301-435-5020;
[email protected]
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to further develop,
evaluate or commercialize Stem Cell Culture Medium. For collaboration
opportunities, please contact Peg Koelble at [email protected].
Dated: February 10, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2014-03083 Filed 2-12-14; 8:45 am]
BILLING CODE 4140-01-P